

Robin Kate Kelley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3345705/publications.pdf>

Version: 2024-02-01

56
papers

12,935
citations

126708

33
h-index

161609

54
g-index

59
all docs

59
docs citations

59
times ranked

9999
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	18.1	2,757
2	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 2018, 379, 54-63.	13.9	1,677
3	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 2022, 76, 681-693.	1.8	1,495
4	Cholangiocarcinoma “evolving concepts and therapeutic strategies. Nature Reviews Clinical Oncology, 2018, 15, 95-111.	12.5	1,051
5	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 796-807.	5.1	620
6	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of Clinical Oncology, 2018, 36, 276-282.	0.8	524
7	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	2.9	416
8	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345.	0.8	350
9	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
10	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. International Journal of Cancer, 2020, 147, 2190-2198.	2.3	288
11	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	0.8	257
12	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	7.7	254
13	Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 995-1008.	5.1	237
14	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. Journal of Clinical Oncology, 2022, 40, 379-379.	0.8	235
15	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discovery, 2015, 5, 1040-1048.	7.7	226
16	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. The Lancet Gastroenterology and Hepatology, 2021, 6, 803-815.	3.7	205
17	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
18	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. Journal of Clinical Oncology, 2017, 35, 4073-4073.	0.8	133

#	ARTICLE	IF	CITATIONS
19	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	5.7	126
20	Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR Aberrations: A Phase I Dose-Expansion Study. <i>Cancer Discovery</i> , 2022, 12, 402-415.	7.7	119
21	Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. <i>BMC Cancer</i> , 2015, 15, 206.	1.1	103
22	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. <i>Oncologist</i> , 2017, 22, 804-810.	1.9	91
23	Harnessing big omics™ data and AI for drug discovery in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 238-251.	8.2	90
24	Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86
25	Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. <i>Cancer</i> , 2019, 125, 3234-3241.	2.0	73
26	Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?. <i>Clinical Colorectal Cancer</i> , 2011, 10, 73-80.	1.0	72
27	Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.. <i>Journal of Clinical Oncology</i> , 2021, 39, 265-265.	0.8	70
28	Hepatocellular Carcinoma – Origins and Outcomes. <i>New England Journal of Medicine</i> , 2021, 385, 280-282.	13.9	60
29	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 4795-4804.	3.2	58
30	Genomic Sequencing: Assessing The Health Care System, Policy, And Big-Data Implications. <i>Health Affairs</i> , 2014, 33, 1246-1253.	2.5	53
31	Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3537-3545.	3.2	52
32	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020, 5, e000714.	2.0	51
33	Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. <i>Cancer</i> , 2019, 125, 4426-4434.	2.0	49
34	Atezolizumab plus Bevacizumab – A Landmark in Liver Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1953-1955.	13.9	44
35	Cabozantinib: An evolving therapy for hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2021, 98, 102221.	3.4	43
36	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43

#	ARTICLE	IF	CITATIONS
37	Final results from ClariDH, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology, 2021, 39, 266-266.	0.8	41
38	Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. Advances in Therapy, 2020, 37, 2678-2695.	1.3	37
39	Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 13-25.	2.3	31
40	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. Cancer Research, 2021, 81, CT010-CT010.	0.4	28
41	Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. Clinical Liver Disease, 2020, 15, 53-58.	1.0	23
42	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 38-47.	4.2	20
43	Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. Lancet Oncology, The, 2015, 16, 1279-1281.	5.1	19
44	ClariDH: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology, 2017, 35, TPS4142-TPS4142.	0.8	17
45	Biliary Tract Cancers: Finding Better Ways to Lump and Split. Journal of Clinical Oncology, 2015, 33, 2588-2590.	0.8	14
46	Cases of Spontaneous Tumor Regression in Hepatobiliary Cancers: Implications for Immunotherapy?. Journal of Gastrointestinal Cancer, 2015, 46, 161-165.	0.6	13
47	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2020, 25, e1825-e1836.	1.9	13
48	Phase II Trial of the Combination of Temezolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer, 2021, 10, 561-571.	4.2	11
49	Novel Therapeutics in Hepatocellular Carcinoma: How Can We Make Progress?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e137-e142.	1.8	10
50	Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. British Journal of Cancer, 2022, 126, 569-575.	2.9	10
51	Predictive Biomarkers in Advance of a Companion Drug: Ahead of Their Time?. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 303-309.	2.3	7
52	A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer Research, 2014, 34, 7357-60.	0.5	7
53	Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. Liver Transplantation, 2012, 18, 509-513.	1.3	5
54	Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. Journal of Molecular Diagnostics, 2022, 24, 351-364.	1.2	5

#	ARTICLE	IF	CITATIONS
55	Drug development in advanced colorectal cancer: Challenges and opportunities. <i>Current Oncology Reports</i> , 2009, 11, 175-185.	1.8	4
56	Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in <i>BRCA1</i> -Mutant Cholangiocarcinoma Harboring a Novel <i>YWHAZ-BRAF</i> Fusion. <i>Oncologist</i> , 2018, 23, 998-1003.	1.9	2